Gujarat Kidney and Super Speciality Ltd

Net profit of Gujarat Kidney & Super Speciality rose 17.60% to Rs 2.94 crore in the quarter ended December 2025 as against Rs 2.50 crore during the previous quarter ended December 2024. Sales rose 97.20% to Rs 23.25 crore in the quarter ended December 2025 as against Rs 11.79 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales23.2511.79 97 OPM %29.6839.02 - PBDT6.364.48 42 PBT5.033.60 40 NP2.942.50 18 Powered by Capital Market - Live

Gujarat Kidney & Super Speciality has postponed the meeting of the Board of Directors which was scheduled to be held on 13 February 2026. The meeting will now be held on 14 February 2026.Powered by Capital Market - Live

Gujarat Kidney & Super Speciality will hold a meeting of the Board of Directors of the Company on 13 February 2026.Powered by Capital Market - Live

The stock debuted at Rs 120.75, marking a premium of 5.92% to the issue price. So far, the stock has hit a high of 123.25 and a low of 114. On the BSE, over 11.13 lakh shares of the company were traded in the counter so far. Gujarat Kidney and Super Speciality was subscribed 5.21 times. The issue opened for bidding on 22 December 2025 and it closed on 24 December 2025. The price band of the IPO was fixed between Rs 108 and 114 per share. The IPO comprised a fresh issue of equity shares, aggregating up to Rs 250.8 crore. The objectives of the fresh issue are to utilize Rs 77 crore towards the acquisition of Parekh's Hospital in Ahmedabad; Rs 12.4 crore will be used for part-payment of the purchase consideration for the already acquired Ashwini Medical Centre; Rs 10.78 crore is earmarked for the acquisition of additional shareholding in the subsidiary, Harmony Medicare, located in Bharuch; Rs 30.09 crore towards funding its capital expenditure requirements; Rs 6.82 crore will be utilized for the purchase of robotics equipment for Gujarat Kidney Rs 1.2 crore will be used for the repayment and/or prepayment of certain outstanding borrowings; and the remaining proceeds will be used for general corporate purposes. The promoters are Dr. Pragnesh Yashwantsinh Bharpoda, Dr. Bhartiben Pragnesh Bharpoda, Dr. Yashwantsingh Motisinh Bharpoda, and Anitaben Yashwantsinh Bharpoda. The promoters and promoter group hold an aggregate of 5,63,33,900 equity shares, aggregating to 99.1% of the pre-offer issued and paid-up equity share capital. Their post-IPO shareholding is expected to be around 71.45%. Ahead of the IPO of Gujarat Kidney and Super Speciality on 22 December 2025, the company raised Rs 100.01 crore from anchor investors by allotting 87.73 lakh shares at Rs 114 each to 10 anchor investors. Gujarat Kidney & Super Speciality specializes in providing multispeciality healthcare services, including secondary and tertiary care, across multiple locations in Gujarat, India. The company operates seven multispecialty hospitals and four pharmacies with a total bed capacity of 490 beds, an approved capacity of 455 beds, and an operational capacity of 340 beds. Comprehensive medical care is provided across a range of specialty and super-specialty services. Treatment is offered across areas such as internal medicine, general surgery, nephrology, urology, cardiology, and orthopedics, while also focusing on advanced super-specialty care, including renal transplantation, vascular surgery, and hematology, among others. Healthcare services are categorized as secondary services, which are surgical services, and tertiary services, which are super specialty surgical services. Central, state, and local government bodies contributed 5.46% to its revenue, insurers through third-party administrators 13.9%, and self-payers and others 80.64% in Q1 FY2026. For the three months ended 30 June 2025, the firm recorded a consolidated net profit of Rs 4.84 crore and income from operations of Rs 15.26 crore.Powered by Capital Market - Live